Compare CUVL & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUVL | ANGO |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | Australia | United States |
| Employees | 16 | N/A |
| Industry | Miscellaneous | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.2M | 420.2M |
| IPO Year | N/A | 2004 |
| Metric | CUVL | ANGO |
|---|---|---|
| Price | $5.25 | $11.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 5.0K | ★ 970.3K |
| Earning Date | 08-27-2026 | 10-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | $0.89 | $5.47 |
| Revenue Next Year | $6.69 | $5.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $4.91 | $9.39 |
| 52 Week High | $8.20 | $16.29 |
| Indicator | CUVL | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 35.40 |
| Support Level | $4.91 | $10.32 |
| Resistance Level | $6.04 | $12.53 |
| Average True Range (ATR) | 0.13 | 0.83 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 23.55 | 25.22 |
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.